CANNABISHUB:EUMedical cannabis research platform

conditions cannabinoids studies medicines library about

Loading researcher profile…

Anonymous aggregate analytics use the connection IP transiently only to derive country; the IP is not stored in analytics data. DNT and GPC are honored, with 90-day retention. IP Geolocation by DB-IP.

Ayşe Doğa Lamper - Medical Cannabis Research Engine

CANNABISHUB:EUMedical cannabis research platform

conditions cannabinoids studies medicines library about

Researchers/Profile

Researcher profile

Ayşe Doğa Lamper

OPENALEX: A5114960566↗

Affiliations

Organizations

King's College Londonauthorship · GB

Public evidence

1 connected articles

Does cannabidiol reduce the adverse effects of cannabis in schizophrenia? A randomised, double-blind, cross-over trial.2025 · Europe PMC

Registered research

Connected studies

Does Cannabidiol Attenuate the Acute Effects of ∆9-tetrahydrocannabinol Intoxication in Individuals Diagnosed With Schizophrenia? A Double-blind, Randomised, Placebo-controlled Experimental Studynct04605393

Matched by exact identifiers only. Profile data: Corpus/OpenAlex.